Merdad  Parsey net worth and biography

Merdad Parsey Biography and Net Worth

Insider of Gilead Sciences
Merdad Parsey, MD, PhD is Gilead’s Chief Medical Officer, responsible for overseeing the company’s global clinical development and medical affairs organizations. In his role, Merdad supervises all clinical trials and development operations. Together with the leadership team, he works to advance clinical development strategies and programs with the goal of changing the trajectory of disease, and transforming care for the patients of today and tomorrow.

Merdad joined Gilead in 2019, after serving as Senior Vice President of Early Clinical Development at Genentech, where he led clinical development for areas including inflammation, oncology and infectious diseases. Prior to Genentech, Merdad served as President and CEO of 3-V Biosciences (now Sagimet BioSciences), held development roles at Sepracor, Regeneron and Merck and was Assistant Professor of Medicine and Director of Critical Care Medicine at the New York University School of Medicine.

He completed his MD and PhD at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

Merdad currently serves on the Board of Directors for Sagimet BioSciences.

What is Merdad Parsey's net worth?

The estimated net worth of Merdad Parsey is at least $6.46 million as of April 1st, 2024. Dr. Parsey owns 96,304 shares of Gilead Sciences stock worth more than $6,461,035 as of May 23rd. This net worth approximation does not reflect any other investments that Dr. Parsey may own. Additionally, Dr. Parsey receives an annual salary of $2,790,000.00 as Insider at Gilead Sciences. Learn More about Merdad Parsey's net worth.

How old is Merdad Parsey?

Dr. Parsey is currently 60 years old. There are 7 older executives and no younger executives at Gilead Sciences. The oldest executive at Gilead Sciences is Dr. Rudolf Ertl, Senior Vice President of Commercial Operations of Australia, Canada, Europe, who is 78 years old. Learn More on Merdad Parsey's age.

What is Merdad Parsey's salary?

As the Insider of Gilead Sciences, Inc., Dr. Parsey earns $2,790,000.00 per year. There are 2 executives that earn more than Dr. Parsey. The highest earning executive at Gilead Sciences is Mr. Daniel P. O'Day, Chairman & CEO, who commands a salary of $6,990,000.00 per year. Learn More on Merdad Parsey's salary.

How do I contact Merdad Parsey?

The corporate mailing address for Dr. Parsey and other Gilead Sciences executives is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. Gilead Sciences can also be reached via phone at (650) 574-3000 and via email at [email protected]. Learn More on Merdad Parsey's contact information.

Has Merdad Parsey been buying or selling shares of Gilead Sciences?

During the last quarter, Merdad Parsey has sold $145,920.00 of Gilead Sciences stock. Most recently, Merdad Parsey sold 2,000 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a transaction totalling $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares of the company's stock, valued at $7,026,339.84. Learn More on Merdad Parsey's trading history.

Who are Gilead Sciences' active insiders?

Gilead Sciences' insider roster includes Gregg Alton (EVP), Paul Carter (EVP), John Cogan (Director), Andrew Dickinson (Exec. VP & CFO ), Andrew Dickinson (CFO), John Martin (Director), Johanna Mercier (Insider), James Meyers (EVP), John Milligan (Insider), Daniel O'Day (Chairman & CEO ), Merdad Parsey (Insider), Brett Pletcher (EVP), Javier Rodriguez (Director), Robin Washington (CFO), Richard Whitley (Director), and Diane Wilfong (CAO). Learn More on Gilead Sciences' active insiders.

Are insiders buying or selling shares of Gilead Sciences?

In the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 30,228 shares worth more than $2,453,404.15. The most recent insider tranaction occured on April, 1st when insider Merdad Parsey sold 2,000 shares worth more than $145,920.00. Insiders at Gilead Sciences own 0.2% of the company. Learn More about insider trades at Gilead Sciences.

Information on this page was last updated on 4/1/2024.

Merdad Parsey Insider Trading History at Gilead Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/1/2024Sell2,000$72.96$145,920.0096,304View SEC Filing Icon  
2/28/2024Sell2,000$73.18$146,360.00100,936View SEC Filing Icon  
9/12/2023Sell1,501$76.99$115,561.9970,130View SEC Filing Icon  
6/13/2023Sell1,485$76.90$114,196.5029,402View SEC Filing Icon  
3/13/2023Sell6,126$78.99$483,892.7470,130View SEC Filing Icon  
3/1/2023Sell12,984$79.96$1,038,200.6470,130View SEC Filing Icon  
8/17/2020Sell182$68.32$12,434.24182View SEC Filing Icon  
See Full Table

Merdad Parsey Buying and Selling Activity at Gilead Sciences

This chart shows Merdad Parsey's buying and selling at Gilead Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Gilead Sciences Company Overview

Gilead Sciences logo
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $66.17
Low: $66.01
High: $67.63

50 Day Range

MA: $68.77
Low: $64.58
High: $74.21

2 Week Range

Now: $66.17
Low: $64.33
High: $87.86

Volume

5,622,931 shs

Average Volume

7,252,690 shs

Market Capitalization

$82.44 billion

P/E Ratio

183.81

Dividend Yield

4.58%

Beta

0.22